Anesth Analg 2001;93:20-27
© 2001 International Anesthesia Research Society
CARDIOVASCULAR ANESTHESIA
The Effects of Heparin, Protamine, and Heparin/Protamine Reversal on Platelet Function Under Conditions of Arterial Shear Stress
Michael J. Griffin, MRCPI, FFARSI*,
Henry M. Rinder, MD ,
Brian R. Smith, MD ,
Jayne B. Tracey ,
Nancy S. Kriz ,
Conan K. Li, PhD , and
Christine S. Rinder, MD*
Departments of *Anesthesiology, Laboratory Medicine, Internal Medicine, and Pediatrics, Yale University School of Medicine and Yale-New Haven Hospital, New Haven, Connecticut; and Xylum Corporation, Scarsdale, New York
Address correspondence and reprint requests to Michael J. Griffin, Assistant Professor, Department of Anesthesiology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520-8051. Address e-mail to michael.griffin{at}yale.edu
Platelet dysfunction contributes to blood loss after cardiopulmonary bypass. This study examined the antiplatelet effects of heparin, protamine, and varying heparin/protamine ratios in an in vitrophysiologic model and further elucidated the mechanism of the antiplatelet and anticoagulant effects of protamine. We used the Clot Signature Analyzer (CSATM), a system that analyzes coagulation in flowing whole blood, to test two aspects of platelet function, with different concentrations of heparin and protamine, under conditions simulating arterial flow: collagen-induced thrombus formation (CITF) under moderate shear and high shear platelet activation, platelet hemostasis time (PHT). In addition, platelet aggregometry, celite activated clotting time (HepconTM ACT), prothrombin time (PT), and partial thromboplastin time (PTT) were measured. Both PHT and the CITF were prolonged by heparin at 20 µg/mL, protamine at 20 and 40 µg/mL, and heparin/protamine ratios of 1:1 and 1:2, but not at 1:1.5. The Hepcon ACT was prolonged by heparin 20 µg/mL and protamine alone at 20 and 40 µg/mL, was normal at a ratio of 1:1, and was prolonged at 1:1.5 and 1:2. Protamine 80 µg/mL prolonged the PT and PTT. Dependency on thrombin, protein kinase C activation, and nonspecific charge effects were examined. The direct thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone prolonged the PHT and ACT, but not the CITF, whereas the polycationic molecules polyarginine and polylysine prolonged the CITF, but not the PHT. The effect of protamine on the PTT, but not PT, could be shortened by the addition of excess phospholipid. Therefore, heparin inhibits both high shear collagen-independent and moderate shear collagen-dependent platelet activation; however, the latter is not mediated by its antithrombin activity. Protamines antithrombin effect may explain its inhibition of platelet activation at high shear stress. Protamines nonspecific charge effects are more important for inhibiting moderate shear collagen-induced platelet activation.
Implications: This study suggests that protamine reversal of heparins antiplateleteffect occurs within a narrow window because of the direct antiplateleteffects of protamine. Antithrombin effects may explain the inhibition of shearactivation of platelets by both heparin and protamine. Nonspecific chargeeffects of protamine may explain the inhibition of collagen plateletactivation in the presence of medium shear.
This article has been cited by other articles:

|
 |

|
 |
 
F. Ni Ainle, R. J. S. Preston, P. V. Jenkins, H. J. Nel, J. A. Johnson, O. P. Smith, B. White, P. G. Fallon, and J. S. O'Donnell
Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation
Blood,
August 20, 2009;
114(8):
1658 - 1665.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Levy and K. A. Tanaka
Anticoagulation and Reversal Paradigms: Is Too Much of a Good Thing Bad?
Anesth. Analg.,
March 1, 2009;
108(3):
692 - 694.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Mittermayr, C. Velik-Salchner, B. Stalzer, J. Margreiter, A. Klingler, W. Streif, D. Fries, and P. Innerhofer
Detection of Protamine and Heparin After Termination of Cardiopulmonary Bypass by Thrombelastometry (ROTEM(R)): Results of a Pilot Study
Anesth. Analg.,
March 1, 2009;
108(3):
743 - 750.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. G. Nielsen
Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation.
Ann. Thorac. Surg.,
May 1, 2006;
81(5):
1720 - 1727.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Mittermayr, J. Margreiter, C. Velik-Salchner, A. Klingler, W. Streif, D. Fries, and P. Innerhofer
Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem(R)): an in vitro study
Br. J. Anaesth.,
September 1, 2005;
95(3):
310 - 316.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F.W. Keuren, S. J.H. Wielders, A. Driessen, M. Verhoeven, M. Hendriks, and T. Lindhout
Covalently-Bound Heparin Makes Collagen Thromboresistant
Arterioscler Thromb Vasc Biol,
March 1, 2004;
24(3):
613 - 617.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
W. C. Oliver Jr
Overview of Heparin and Protamine Management and Dosing Regimens in Pediatric Cardiac Surgical Patients
Seminars in Cardiothoracic and Vascular Anesthesia,
December 1, 2003;
7(4):
387 - 410.
[Abstract]
[PDF]
|
 |
|
|